Trial Information
Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy
Inclusion Criteria:
- Histologically confirmed diagnosis of MPM (all subtypes)
- Clinical T1-3, N0-2, M0 disease.
- No prior treatment for MPM.
- Adequate renal and liver function
- Adequate cardio-pulmonary reserves
Exclusion Criteria:
- Patients with unresectable disease
- Patients with an active infection that require systemic treatments
- Patients with a concurrent active malignancy.
- Patients with serious medical illness.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To determine the overall 5-year survival rate.
Outcome Time Frame:
5-years
Safety Issue:
Yes
Principal Investigator
Joachim Schirren, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
HSK Wiesbaden
Authority:
Germany: Ethics Commission
Study ID:
RP2002-01
NCT ID:
NCT01343264
Start Date:
November 2002
Completion Date:
Related Keywords:
- Malignant Pleural Mesothelioma
- Radical Pleurectomy
- Pleurectomy/decortication
- Cisplatin
- Pemetrexed
- Radiation
- Mesothelioma